Value of Rituximab in Humoral Chronic Rejection After Renal Transplantation
Status:
Terminated
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the benefit of rituximab in patients with CAN with histologically proven C4d
deposits and/or plasma cell and/or B-Lymphocyte (CD20+ cells) infiltration of their grafts.
Phase:
Phase 2
Details
Lead Sponsor:
Technische Universität München
Collaborators:
Heidelberg University Heinrich-Heine University, Duesseldorf Humboldt-Universität zu Berlin Martin-Luther-Universität Halle-Wittenberg Transplantationszentrum Köln-Merheim University Hospital Freiburg University Hospital, Essen University of Erlangen-Nürnberg University of Jena University of Regensburg